source
- ArriVent's lead lung cancer drug firmonertinib fails Phase 3 trial, shares plungeArriVent BioPharma announced that its flagship EGFR inhibitor, firmonertinib, did not meet primary endpoints in a late-stage Phase 3 study for lung cancer. The trial results were released on Octobe…
- AI investments in healthcare delivering returns faster than executives anticipatedA new report from Bessemer Venture Partners finds that artificial-intelligence projects in health-care are delivering benefits more quickly than industry leaders expected. The survey highlights th…